CommercialCoverageMedium impact
08.01.79g, Dostarlimab-gxly (Jemperli)
Independence Blue Cross·Oncology, Hematology, Pharmacy·Pharmacy
Effective date
Jun 1, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross expanded dostarlimab-gxly (Jemperli) coverage effective 06/01/2026 by adding two new cancer indications (appendiceal neoplasms and non-small cell lung cancer) and revising medical necessity criteria for eight existing cancer types based on updated NCCN guidelines. Billing teams must verify patient eligibility against the updated criteria for all covered indications before claims submission.
Action Required
By 05/15/2026: Billing team must update documentation requirements and prior authorization protocols in the billing system to reflect the expanded indications for HCPCS code J9272. (1) Review updated medical necessity criteria for all 15 covered cancer types, particularly the two newly added indications (appendiceal neoplasms and non-small cell lung cancer). (2) Verify that prior authorization submissions for J9272 include documentation of dMMR/MSI-H status (or applicable genetic markers for new indications) per FDA-approved testing. (3) For ampullary adenocarcinoma, anal carcinoma, colon cancer, endometrial cancer, esophageal/esophagogastric junction cancer, gastric cancer, occult primary cancer, and small bowel adenocarcinoma, confirm that claim submissions reference the revised NCCN guideline versions cited in the policy. (4) Update encounter forms and EMR templates to capture required performance status documentation (ECOG or Karnofsky). (5) Train billing staff on the specific combination therapy scenarios for anal carcinoma (with paclitaxel and carboplatin). Claims submitted without updated eligibility verification or missing required genetic/performance status documentation will be delayed or denied.